()
Friday’s FDA Webcast on NASH drug development provided few concrete answers but several clues and directions to pursue. Listen as Manal Abdelmalek, Naim Alkhouri, and Kitty Yale, Chief Development Officer at Akero Therapeutics, join the Surfers to read the tea leaves and identify fruitful areas for further research and pursuit. Issues around diagnostics and the risk: benefit tradeoff received particular attention.
How useful was this post?
Click on a star to rate it!
Average rating / 5. Vote count:
No votes so far! Be the first to rate this post.